Safety and Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: A Single Center Experience-Reference-Cited by-同舟云学术

Safety and Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: A Single Center Experience

Published:2023-06 Issue: Volume:Volume 10 Page:883-892
ISSN:2253-5969
Container-title:Journal of Hepatocellular Carcinoma
language:en
Short-container-title:JHC

Author:

Pan Xian,Wu Shao-Jie,Tang Yi,Zhou Yan-Feng,Luo Jie-Wei,Fang Zhu-Ting

Publisher

Informa UK Limited

Subject

General Medicine

Reference33 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Epidemiology and Management of Hepatocellular Carcinoma

3. HBV induced hepatocellular carcinoma and related potential immunotherapy

4. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)

5. Idarubicin‐Loaded DEB‐TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score‐matching analysis

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis;BMC Cancer;2024-08-14

2. Clinical benefits of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors for unresectable hepatocellular carcinoma;World Journal of Gastrointestinal Oncology;2024-07-15

3. Case report: Complete response after transcatheter arterial chemoembolization combined with donafenib plus tislelizumab therapy for hepatocellular carcinoma with main trunk portal vein tumor thrombus in a patient coinfected with HIV and HBV;Frontiers in Immunology;2024-07-15

4. Portal Venous and Hepatic Arterial Coefficients Predict Post-Hepatectomy Overall and Recurrence-Free Survival in Patients with Hepatocellular Carcinoma: A Retrospective Study;Journal of Hepatocellular Carcinoma;2024-07

5. TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study;BMC Cancer;2024-06-11